SEC Company Response from VOLITIONRX LTD (VNRX) (CIK 0000093314) (VNRX) — Sep 26, 2018
VOLITIONRX LTD (VNRX) (CIK 0000093314)
Date: Sept. 26, 2018 · CIK: 0000093314 · Accession: 0001078782-18-001074
AI Filing Summary & Sentiment
File numbers found in text: 333-227248
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request VOLITIONRX LIMITED 1 Scotts Road #24-05 Shaw Centre Singapore 228208 September 26, 2018 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dorrie Yale Re:VolitionRx Limited Acceleration Request Registration Statement on Form S-3 File No. 333-227248 Requested Date:September 28, 2018 Requested Time:5:00 P.M. Eastern Time Dear Ms. Yale: Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), VolitionRx Limited, a Delaware corporation (the “Company”), hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable. Should the Commission have any questions regarding this acceleration request, please do not hesitate to contact Marc G. Alcser, an attorney with the Company’s outside legal counsel, Stradling Yocca Carlson & Rauth, P.C., via telephone at (949) 725-4136 or via email at malcser@sycr.com. Sincerely, VOLITIONRX LIMITED /s/ Cameron Reynolds Cameron Reynolds President and Chief Executive Officer cc: Stradling Yocca Carlson & Rauth, P.C. Marc G. Alcser, Esq.